Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20470599 | 0.97 | CA12 (0.50) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL27652381 | 0.92 | CA12 (0.46) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL26560789 | 0.79 | CA12 (0.50) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL108245 | 0.77 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL4442972 | 0.73 | CA12 (0.44) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL995945 | 0.71 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL19413262 | 0.69 | CA12 (0.52) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL19413304 | 0.69 | CA12 (0.52) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL4724826 | 0.69 | CA12 (1.00) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL18963225 | 0.69 | CA12 (0.52) | CA12CA7CA14SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245089-A1 | PROCESSES FOR PREPARING TETRALIN COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4200309-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | ATEA Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | claimed |
| CN-109803952-B | Sulfamic acid derivatives and process for preparing same | 魁北克电力公司 | 2022-10-04 | — | — | CN | claimed |
| CN-112279785-B | 3, 3-difluorocyclobutylamine hydrochloride intermediate and synthetic method thereof, and 3, 3-difluorocyclobutylamine hydrochloride synthetic method | 苏利制药科技江阴有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-114671848-A | Synthetic method of aromatic fused oxygen sulfur heterocyclic compound | 郑州药领医药科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| US-11345657-B2 | Sulfamic acid derivatives and processes for their preparation | HYDRO-QUEBEC (CA) | 2022-05-31 | — | — | US | claimed |
| WO-2022040473-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2022-02-24 | — | — | WO | claimed |
| CN-100543032-C | Streptogramin derivatives, preparation method and compositions containing them | AVETIS PHARMA S A (FR) | 2009-09-23 | — | — | CN | claimed |
| EP-1723091-B1 | SYNTHESIS OF CARBON-LABELED PERFLUOROALKYL COMPOUNDS | DU PONT (US) | 2008-11-05 | — | — | EP | claimed |
| CN-101233098-A | Process for the preparation of geminal ((difluorocycloalkyl) methyl) amines | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | CN | claimed |
| US-20080167488-A1 | Process for the Preparation of Geminal ((Difluorocycloalkyl)Methyl) Amines | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | claimed |
| EP-1912930-A1 | PROCESS FOR THE PREPARATION OF GEMINAL ((DIFLUOROCYCLOALKYL)METHYL) AMINES. | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | claimed |
| US-7351870-B2 | Synthesis of carbon-labeled perfluoroalkyl compounds | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-04-01 | — | — | US | claimed |
| WO-2007013848-A1 | PROCESS FOR THE PREPARATION OF GEMINAL ((DIFLUOROCYCLOALKYL)METHYL) AMINES. | ASTRAZENECA AB (SE) | 2007-02-01 | — | — | WO | claimed |
| EP-1723091-A2 | SYNTHESIS OF CARBON-LABELED PERFLUOROALKYL COMPOUNDS | E.I.Du pont de nemours and company (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005092820-A2 | SYNTHESIS OF CARBON-LABELED PERFLUOROALKYL COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-10-06 | — | — | WO | claimed |
| US-20050197510-A1 | Synthesis of carbon-labeled perfluoroalkyl compounds | THE CHEMOURS COMPANY FC, LLC | 2005-09-08 | — | — | US | claimed |
| CN-1358194-A | Streptogramin derivatives, preparation method and compositions containing them | AVETIS PHARMA S A (FR) | 2002-07-10 | — | — | CN | claimed |
| CN-1137797-A | Rapamycin derivatives useful as immunosuppressants | SANDOZ LTD (CH) | 1996-12-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167488-A1 | Process for the Preparation of Geminal ((Difluorocycloalkyl)Methyl) Amines | GMNN, GNMT, DNMT1 | CA12 3328/4885CA7 4001/4885CA14 3827/4885 |
| US-11345657-B2 | Sulfamic acid derivatives and processes for their preparation | STS, SCLY, MPST | CA12 57/4885CA7 76/4885CA14 59/4885 |
| US-20050197510-A1 | Synthesis of carbon-labeled perfluoroalkyl compounds | ZYX, CYP2F1, AFF1 | CA12 1243/4885CA7 900/4885CA14 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.